23.38

1.52% -0.36

Nurix Therapeutics Inc (NRIX)

Overview News Price History Option Chain Financials Discussions Forecast

Nurix Therapeutics Inc stock is traded at $23.38, with a volume of 833.10K. It is down -1.52% in the last 24 hours and up +21.14% over the past month. Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Previous Close:

$23.74

Open:

$23.93

24h Volume:

833.10K

Relative Volume:

0.45

Market Cap:

$2.43B

Revenue:

$71.78M

Net Income/Loss:

$-295.28M

P/E Ratio:

-7.3994

EPS:

-3.1597

Net Cash Flow:

$-271.85M

1W Performance:

+1.12%

1M Performance:

+21.14%

6M Performance:

+25.97%

1Y Performance:

+102.78%

1-Day Range:

$23.10

$24.00

1-Week Range:

$22.64

$24.17

52-Week Range:

$8.195

$24.95

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name

Nurix Therapeutics Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

(415) 660-5320

Address

1600 SIERRA POINT PKWY, BRISBANE

Employee

357

Twitter

Next Earnings Date

2026-07-08

Latest SEC Filings

NRIX's Discussions on Twitter

Compare NRIX vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRIX Nurix Therapeutics Inc	23.38	2.43B	71.78M	-295.28M	-271.85M	-3.1597
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-24-25	Resumed	Truist	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Mar-17-25	Initiated	Leerink Partners	Market Perform
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Oct-24-24	Initiated	UBS	Buy
Oct-11-24	Initiated	Jefferies	Buy
Sep-06-24	Resumed	Robert W. Baird	Outperform
Jul-31-24	Initiated	Truist	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-09-23	Initiated	Barclays	Overweight
Feb-28-23	Initiated	Oppenheimer	Outperform
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Dec-29-21	Initiated	H.C. Wainwright	Buy
Oct-14-21	Initiated	SVB Leerink	Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-30-21	Resumed	Piper Sandler	Overweight
Apr-30-21	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Needham	Buy
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Stifel	Buy

View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

Jul 23, 2026

NRIX: Nurix Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Jul 23, 2026

Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - GlobeNewswire Inc.

Jul 23, 2026

Jul 22, 2026

NRIX Maintained by UBS -- Price Target Raised to $31 - GuruFocus

Jul 22, 2026

UBS Lifts Nurix Therapeutics Price Target to $31 From $23, Maintains Buy Rating - Moomoo

Jul 22, 2026

UBS Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $31 - Moomoo

Jul 22, 2026

Why Did Nurix Therapeutics (NASDAQ:NRIX) Announce Key Clearance? - Kalkine Media

Jul 22, 2026

Jul 21, 2026

Nurix closes $700m Roche collaboration for bexobrutideg - Investing.com

Jul 21, 2026

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology - The Manila Times

Jul 21, 2026

Nurix to Receive $700M Upfront in Roche Bexobrutideg Deal - Stock Titan

Jul 21, 2026